caa a22 4500 469104309 CHVBK 20180323133052.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF00770616 doi (NATIONALLICENCE)springer-10.1007/BF00770616 A system for searching for and studying compounds with antimutagenic properties (methodological recommendations) [Elektronische Daten] [N. Bochkov, A. Durnev, V. Zhurkov, A. Malashenko, Yu. Revazova, S. Seredenin] Conclusions: Conclusions on whether or not a given compound has a protective effect are made on the basis of all the experimental results obtained. The compound is considered to have potential for further pharmacological development as an agent able to protect genetic structures only when it is found to have protective actions in all the tests and when the level of protection is at least 50%. The detection of antimutagenic properties is not a direct indication for using a substance in man as a corrector of mutagenesis. Practical use of a protector is only possible after it has been studied by a complete program of pre-clinical investigations for new drugs, and when its antimutagenic effects have been confirmed in clinical trials. When a known drug is used as a mutagenesis corrector, the quantity of pre-clinical studies can be reduced in accordance with the Commission for the Evaluation of the Safety of New Therapeutic Substances of the Pharmacology Committee. The present methodological recommendations are approved by the "Problems in Mutagenesis” Working Commission, which met on 25-26 December 1991 in Moscow, on the initiative of the Presidium of the Russian Academy of Medical Sciences. Plenum Publishing Corporation, 1993 Bochkov N. Scientific-Research Institute of Pharmacology, I. M. Sechenov Moscow Medical Academy, USSR aut Durnev A. Scientific-Research Institute of Pharmacology, I. M. Sechenov Moscow Medical Academy, USSR aut Zhurkov V. Scientific-Research Institute of Pharmacology, I. M. Sechenov Moscow Medical Academy, USSR aut Malashenko A. Scientific-Research Institute of Pharmacology, I. M. Sechenov Moscow Medical Academy, USSR aut Revazova Yu Scientific-Research Institute of Pharmacology, I. M. Sechenov Moscow Medical Academy, USSR aut Seredenin S. Scientific-Research Institute of Pharmacology, I. M. Sechenov Moscow Medical Academy, USSR aut Pharmaceutical Chemistry Journal Kluwer Academic Publishers-Plenum Publishers 26/9-10(1992-09-01), 711-716 0091-150X 26:9-10<711 1992 26 11094 https://doi.org/10.1007/BF00770616 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00770616 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Bochkov N. Scientific-Research Institute of Pharmacology, I. M. Sechenov Moscow Medical Academy, USSR aut NATIONALLICENCE 700 1- Durnev A. Scientific-Research Institute of Pharmacology, I. M. Sechenov Moscow Medical Academy, USSR aut NATIONALLICENCE 700 1- Zhurkov V. Scientific-Research Institute of Pharmacology, I. M. Sechenov Moscow Medical Academy, USSR aut NATIONALLICENCE 700 1- Malashenko A. Scientific-Research Institute of Pharmacology, I. M. Sechenov Moscow Medical Academy, USSR aut NATIONALLICENCE 700 1- Revazova Yu Scientific-Research Institute of Pharmacology, I. M. Sechenov Moscow Medical Academy, USSR aut NATIONALLICENCE 700 1- Seredenin S. Scientific-Research Institute of Pharmacology, I. M. Sechenov Moscow Medical Academy, USSR aut NATIONALLICENCE 773 0- Pharmaceutical Chemistry Journal Kluwer Academic Publishers-Plenum Publishers 26/9-10(1992-09-01), 711-716 0091-150X 26:9-10<711 1992 26 11094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer